Restricted accessResearch articleFirst published online 2018-10
ISMP Adverse Drug Reactions: Adalimumab-Induced Aseptic Meningitis Pill Desiccant -Induced Acute Hypoxic Respiratory Failure Rivastigmine Patch -Induced Angioedema Acute Liver Failure Due to Etodolac Severe Cognitive Impairment Due to High Free Valproic Acid Levels
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of revention, and promote reporting of ADRs to the US Food and Drug Administration’s (FDA) MedWatch program (800-ßDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with ur readers. E-mail Dr.Mancanomichael.mancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA’s MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.
Get full access to this article
View all access options for this article.
References
1.
WangDYChongWSPanJYHengYK.First Case report of aseptic meningitis induced by adalimumab administered for treatment of chronic plaque psoriasis. J Investig Allergol Clin Immunol. 2018;27(3):183-185.
2.
GersteinWLiuZ.Visually impaired elderly patient ingests pill desiccant, leading to acute hypoxic respiratory failure requiring intubation. BMC Geriatr. 2017;17:166.
3.
NaharciMI.Angioedema caused by rivastigmine patch: a rare case. J Clin Psychopharmacol. 2018;38(3):281-282.
4.
TanejaSKumarPRathiSet al. Acute liver failure due to etodolac, a selective cycloxygenase-2 (COX-2) inhibitor non-steroidal anti-inflammatory drug established by RUCAM-based causality assessment. Ann Hepatol. 2017;16(5):818-821.
5.
DautzenbergGNederlofMBeekmanAet al. Severe cognitive impairment associated with a high free but therapeutic total concentration of valproic acid due to hypoalbuminemia in an older patient with bipolar disorder. J Clin Psychopharmacol. 2018;38(3):265-267.
